Tau-Centric Multitarget Approach for Alzheimer’s Disease: Development of First-in-Class Dual Glycogen Synthase Kinase 3β and Tau-Aggregation Inhibitors-Reference-Cited by-同舟云学术

Tau-Centric Multitarget Approach for Alzheimer’s Disease: Development of First-in-Class Dual Glycogen Synthase Kinase 3β and Tau-Aggregation Inhibitors

Published:2018-08-04 Issue:17 Volume:61 Page:7640-7656
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Gandini Annachiara¹²,Bartolini Manuela¹,Tedesco Daniele¹,Martinez-Gonzalez Loreto³,Roca Carlos³,Campillo Nuria E.³^ORCID,Zaldivar-Diez Josefa³,Perez Concepción⁴,Zuccheri Giampaolo¹⁵,Miti Andrea¹⁵^ORCID,Feoli Alessandra⁶,Castellano Sabrina⁶,Petralla Sabrina¹,Monti Barbara¹,Rossi Martina²,Moda Fabio⁷,Legname Giuseppe²,Martinez Ana³^ORCID,Bolognesi Maria Laura¹^ORCID

Affiliation:

1. Department of Pharmacy and Biotechnology, Alma Mater Studiorum—University of Bologna, Via Belmeloro 6, I-40126 Bologna, Italy

2. Laboratory of Prion Biology, Department of Neuroscience, Scuola Internazionale Superiore di Studi Avanzati (SISSA), Via Bonomea 265, I-34136 Trieste, Italy

3. Centro de Investigaciones Biologica, CSIC, Ramiro de Maeztu 9, 28040 Madrid, Spain

4. Instituto de Quimica Medica, CSIC, Calle Juan de la Cierva 3, 28006 Madrid, Spain

5. S3 Center of the Institute of Nanosciences, Italian National Research Council (CNR), I-41125 Modena, Italy

6. EpigeneticMedChemLab, Department of Pharmacy, University of Salerno, Via Giovanni Paolo II 132, I-84084 Fisciano, Italy

7. Fondazione IRCCS Istituto Neurologico Carlo Besta, via Celoria 11, I-20133 Milan, Italy

Funder

Ministerio de Econom?a y Competitividad

Universit? di Bologna

Ministero della Salute

European Cooperation in Science and Technology

MJFF, ALZ, Alzheimer???s Research UK and the Weston Brain Institute

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.8b00610

Reference99 articles.

1. Alzheimer’s disease drug-development pipeline: few candidates, frequent failures

2. Neuroregeneration versus neurodegeneration: toward a paradigm shift in Alzheimer's disease drug discovery

3. Dolsten, M. Learn more about our neuroscience R&D decision; Pfizer Worldwide Research and Development, January 11, 2018; https://www.pfizer.com/news/featured_stories/featured_stories_detail/learn_more_about_our_neuroscience_r_d_decision (accessed July 12, 2018).

4. Pathways towards and away from Alzheimer's disease

5. Alzheimer's disease, a multifactorial disorder seeking multitherapies

Cited by 89 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design, synthesis, and biological evaluation of tetrahydropyrimidine analogue as GSK-3β/Aβ aggregation inhibitor and anti-Alzheimer’s agent;Bioorganic Chemistry;2024-12

2. Current development and structure–activity relationship study of berberine derivatives;Bioorganic & Medicinal Chemistry;2024-10

3. Recent Molecular Targets and Their Ligands for the Treatment of Alzheimer Disease;Current Topics in Medicinal Chemistry;2024-08-20

4. Unlocking hope: GSK-3 inhibitors and Wnt pathway activation in Alzheimer’s therapy;Journal of Drug Targeting;2024-06-11

5. Innovative pathological network‐based multitarget approaches for Alzheimer's disease treatment;Medicinal Research Reviews;2024-04-28